BioNTech is tearing up the script. The German biotech, still synonymous with the COVID-19 vaccine it developed with Pfizer, has embarked on a sweeping corporate overhaul that sees its founders walk away with hundreds of researchers while the company slashes nearly a quarter of its workforce. The moves, announced in tandem, signal just how aggressively the Mainz-based group is betting its future on oncology.
The clock is now ticking on a binding contract for the founder spin-off. Ugur Sahin and Özlem Türeci are preparing to exit the company they built, taking roughly 300 specialised scientists with them into a new independent venture focused on early-stage mRNA innovation. BioNTech will contribute technology in exchange for a minority stake and future royalty payments. The deal is expected to be finalised by the end of June 2026. Meanwhile, the supervisory board has hired executive search firm Egon Zehnder to find a new chief executive who can steer the commercialisation of the company’s cancer pipeline.
The restructuring doesn’t stop at the C-suite. With demand for COVID vaccines in freefall, BioNTech is shuttering production sites in Marburg, Idar-Oberstein and Tübingen in Germany, as well as its factory in Singapore. The closures will eliminate around 1,860 jobs — roughly 22 percent of the total headcount — with the German sites winding down by the end of 2027 and Singapore shortly before. The company plans to sell the facilities, targeting annual cost savings of roughly half a billion euros from 2029.
Those savings are sorely needed. First-quarter 2026 brought a net loss of $622 million as revenue from the COVID franchise continued to shrink. Yet BioNTech’s balance sheet remains formidable: it entered the year with around $17 billion in cash. That war chest is being poured directly into research and development, which hit $651 million in the latest quarter. By year-end, the company aims to have 15 phase III clinical trials underway, including late-stage candidates such as the bispecific antibody Pumitamig and the checkpoint inhibitor Gotistobart.
Early data on both drugs was unveiled at this year’s ASCO conference, and for a company in transition, it was a critical moment. Pumitamig delivered positive results when combined with chemotherapy in lung cancer patients. Gotistobart showed promise as a chemotherapy-free option in ovarian cancer. These aren’t blockbuster approvals yet, but they give the pipeline a tangible shape that the market has been demanding.
Should investors sell immediately? Or is it worth buying BioNTech?
Investors, however, have been slow to reward the effort. BioNTech’s shares on the Frankfurt exchange are trading at €74.70, a level that barely budges from recent lows. The stock has lost nearly 19 percent over the past year. Technically, the picture is grim: the price sits well below both the 50-day moving average of €81.02 and the 200-day average at €85.64, while the relative strength index at 37.2 signals continued selling pressure. The Nasdaq-listed American depositary receipts are faring slightly better at around $86.50, helped by a multibillion-dollar share buyback programme.
Yet the sell-off has been orderly rather than panicked. Analysts note that the stock is just over 9 percent above its 52-week low of €68.35, suggesting the market is pricing in heavy uncertainty but not a terminal decline. The typical verdict: BioNTech is being treated not as a pandemic winner anymore, but as a biotech in the painful middle of reinvention. The COVID business, now seasonal and subject to shifting regulatory demands like the FDA’s call for updated vaccines, still provides a revenue floor, but it can no longer lift the stock.
The core tension is one of timing. BioNTech has a deep pipeline and a cash pile that few biotechs can match. What it lacks is a blockbuster oncology product that has crossed the regulatory finish line. Until that happens, the market will keep demanding proof. The ASCO data moved the needle conceptually, but not on the price chart. As one strategist put it, the stock is a patience play — and the market has never been patient with potential.
With a binding founder spin-off contract due in less than three months, and the search for a new chief executive accelerating, BioNTech is entering a period of maximum flux. The founders’ departure could be read as a vote of confidence in the early-stage science or as a sign that the commercialisation phase requires a different leadership style. Either way, the company’s $17 billion cushion gives it room to experiment. The next big test will come when the first of those 15 phase III trials reads out. Until then, the shares are likely to drift — waiting for a catalyst that can turn pipeline promise into revenue reality.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from June 11 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 11.
BioNTech: Buy or sell? Read more here...
